Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may forecast life-threatening clots or bleeds on ECMO

NCT ID NCT06095518

Knowledge-focused Sponsor: Queen Mary Hospital, Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This pilot study investigates whether certain blood markers (DIC markers and thrombin generation parameters) can predict thrombotic and hemorrhagic complications in adults on ECMO life support. Researchers will observe these markers in patients with and without complications. The goal is to find early warning signs that could improve management of ECMO patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict and prevent dangerous bleeding or clotting events in patients on ECMO.
What could go wrong
This is a small pilot study with only 49 participants, so results may not apply broadly. The markers may not reliably predict complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

49 people

The number who actually took part.

Started

May 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients requiring ECMO support

Ages

Up to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≧ 18; AND * Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital or Tuen Mun Hospital in Hong Kong; AND * Require either veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support. Exclusion Criteria: * Patients who are on central VA-ECMO support; OR * Patients with missing clinical data; OR * Patients with pre-existing thromboembolism requiring long term anticoagulation prior to ECMO cannulation; OR * Post-operative admissions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extracorporeal circulation; complications are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemorrhage thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extracorporeal circulation; complications Extracorporeal membrane oxygenation complication

Contacts and locations

Locations

  • Queen Mary Hospital

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.